J. Edward Moreno is a journalist who writes for The New York Times and has also been featured in publications such as The Seattle Times, Honolulu Star-Advertiser, and Bloomberg Law. He specializes in covering legal trials, financial news, and the stock market, providing in-depth analysis and reporting on high-profile cases and market trends.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
J. Edward Moreno focuses on legal and compliance aspects, with a significant portion of his coverage being government announcements and legal policy regulation in the context of stock markets, investing, market analysis, trends, and outlook.
Given this focus, he is likely to be interested in receiving pitches from individuals who can provide insights into legal or regulatory developments impacting the financial sector. The ability to provide data-driven analysis or commentary on how specific regulations may impact market trends would likely resonate well with him.
Since J. Edward's themes are broad but include a focus on tech as well as crypto & blockchain topics alongside stocks and investing, experts able to discuss the intersection between these areas could also capture his interest. It appears that J. Edward does not have a specific geographic focus but takes an international view of financial regulations affecting various markets globally.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: J. Edward Moreno
“This is probably the first time in their history that the US is deeply reliant on Mexico.”...
By: J. Edward Moreno
Anthem walked back its new cap on anesthesia coverage set to go into effect in Connecticut, New York, and Missouri. The insurer had announced...
By: Edward Moreno
Build-A-Bear Workshop silently rose from the pandemic as a profit-making machine.
The move comes as competition for market share for EVs is intensifying, with most traditional combustion vehicle makers releasing their own EV...
Micron Technology is down more than 12% after hours on Wednesday after the Idaho-based chipmaker reported weaker-than-expected earnings and a grim forecast for next year.
The union said the company isn't nearly as eager to pay its baristas more as it was when it penned its new CEO's pay package....
Back in 2007, the US housing market was about to fall off a cliff and “Irreplaceable” by Beyoncé was the song of the year.
Constellation Brands’ portfolio of popular Mexican beers may not be enough to offset its shrinking wine and spirits sector....
Johnson & Johnson announced Monday that it would acquire drugmaker Intra-Cellular Therapies for $14.6 billion, marking its latest bid for growth via swallowing a smaller company.
By: Edward Moreno
The 15 drugs include GLP-1s like Ozempic and Wegovy and were used by over 5 million Americans.
(833) 317-6278 
